The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, ...

Matt Adams has become the new chief executive at BrainScope, taking over from Laurie Silver, who becomes the medical ...

Questex has acquired The Conference Forum and Versalinx Global Events, two highly respected organizers known for convening ...

Last Thursday brought the shock announcement that Novo Nordisk had made a fresh play to buy the biotech, despite Pfizer ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Harmony also touts late-stage asset EPX-100 (clemizole hydrochloride), which the biotech is running through a pair of phase 3 trials in Dravet syndrome and Lennox-Gastaut Syndrome— both rare forms of ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into ...

Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

The precision oncology biotech is pausing work on SMARCA2 degraders and selling a licensing option to Incyte Therapeutics.

Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody. | ...